Access Pharmaceuticals signs agreement to manufacture its FDA-approved MuGard in the United States

DALLAS, TX, September 11, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution.  One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.
Read more »

MuGard, North America, Strategic partnerships

Access Pharmaceuticals provides update on ProLindac™ clinical development plan

Finalizing plans for combination studies in liver, pancreatic and ovarian cancers

Dallas, TX September 10, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), provided an update today on the Company’s clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.  Access’ clinical development team recently met with its partners Aosaikang Medicinal Group (ASK) in Nanjing, China and JCOM, Ltd. (“JCOM”) in Seoul, Korea, together with key opinion leaders in oncology indications to discuss the protocols for the three planned ProLindac combination studies.  Access and its partners are finalizing development plans and protocols for clinical trials strategically designed to examine ProLindac in combination with gemcitabine and/or taxol in hepatocellular carcinoma (a form of liver cancer), pancreatic cancer and recurrent ovarian cancer.
Read more »

Asia, Clinical data, ProLindac, Product programs, Strategic partnerships

Access Pharmaceuticals to present at the Rodman & Renshaw Annual Healthcare Conference

Access to Provide Update on MuGard Global Commercial Launch and ProLindac Clinical Development Plans

Dallas, TX, September 1, 2009

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced today that Access will present at the Rodman & Renshaw 11th Annual Healthcare Conference to be held September 9-11, 2009 at the New York Palace Hotel in New York City.  Jeffrey B. Davis, President and CEO of Access is scheduled to speak on Friday, September 11, 2009 at 10:50 am EDT in the Fahnestock Salon (5th Floor) and will give a corporate overview and discuss the Company’s product opportunities.
Read more »

Calendar and Coverage, Product programs, Strategic partnerships

Access Pharmaceuticals, Inc. CEO, Jeffrey B. Davis interviewed by CorporateProfile.com

Interview focuses on market potential for MuGard

September 1, 2009

Jeffrey B. Davis, President and Chief Executive Officer of Access Pharmaceuticals, Inc. (OTCBB: ACCP) was recently interviewed by CorporateProfile.com reporter Janaye Ingram.

Click here to watch the interview on Corporate Profile.com, or watch it below.

Read more »

Calendar and Coverage, MuGard

© Access Pharmaceuticals 2010 | Disclaimer